Authernative Granted U S Patent: related news

Authernative Granted U.S. Patent

Authernative, Inc., developer of user and transaction authentication and identity management technologies, announced that the United States Patent & Trademark Office has granted the company a patent for a private and secure financial transactions method. The patent describes an enhanced security and fraud protection system, which enables financial account holders to perform secure financial transactions with or without disclosing private financial or personal information to merchants or sellers. The method describes a transaction-processing architecture for performing secure in-person, offline, online, or mobile financial transactions with the direct participation of the account holder's financial account. The patent also introduces a random partial PIN/password recognition algorithm to authenticate the account holder.

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling...

Surfware, Inc. Announces U.S. Patent Office Notice of Allowance for Engagement Milling (TrueMill) CAMARILLO, Calif., Aug. 19 /PRNewswire/ -- Surfware, Inc., developer of innovative CAD/CAM software for machining, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its Engagement Milling technology. A Notice of Allowance signifies that the application has been examined and is allowed for issuance as a patent. The U.S. Patent Office accepted all key aspects of the company's patent application. "We are pleased to receive this Notice of Allowance because it serves to protect the intellectual property and proprietary technology that we have developed," says Stephen Diehl, President and CEO of Surfware.

DP6946 Patent Thickets and the Market for Innovation: Evidence from Settlement of Patent Disputes

We study how fragmentation of patent rights (‘patent thickets’) and the formation of the Court of Appeal for the Federal Circuit (CAFC) affected the duration of patent disputes, and thus the speed of technology diffusion through licensing. We develop a model of patent litigation which predicts faster settlement agreements when patent rights are fragmented and when there is less uncertainty about court outcomes, as was associated with the ‘pro-patent shift’ of CAFC. The model also predicts that the impact of fragmentation on settlement duration should be smaller under CAFC. We confirm these predictions empirically using a dataset that covers nearly all patent suits in U.S. federal district courts during the period 1975-2000. Finally, we analyze how fragmentation affects total settlement delay, taking into account both reduction in duration

Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM)

announced today the issuance of U.S. Patent No. 7,410,978 (the "'978 patent"), entitled "Once Daily Dosage Forms of Trospium," which is licensed exclusively to the Company by the patent's assignee, Supernus Pharmaceuticals, Inc. The '978 patent covers the Company's approved product, SANCTURA XR(TM), a once-a-day formulation of trospium chloride which is indicated for the treatment of symptoms of an overactive bladder. Based on calculations made by the United States Patent and Trademark Office, the term of the '978 patent is twenty years plus 89 days from its filing date of November 4, 2004, or February 1, 2025. In September 2007, the Company entered into an agreement with Allergan, Inc. by which the Company granted Allergan an exclusive sublicense to market SANCTURA XR in the United States.

Santarus Announces Issuance Date of Additional U.S. Patent

Santarus, Inc. SNTS, a specialty pharmaceutical company, today announced that its licensor, the University of Missouri, has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent application number 10/641,732 will issue on July 15, 2008 as U.S. patent number 7,399,772. The new patent has claims covering methods for treating acid-caused gastrointestinal disorders by administering a solid pharmaceutical composition comprising non-enteric coated omeprazole and certain antacids. A Notice of Allowance was sent by the USPTO in April 2008. The new patent will have a July 2016 expiration date.

Santarus Announces Issuance Date of Additional U.S. Patent Covering Zegerid Products

SAN DIEGO--(BUSINESS WIRE)--Jul 8, 2008 - Santarus, Inc. (NASDAQ:SNTS), a specialty pharmaceutical company, today announced that its licensor, the University of Missouri, has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent application number 10/641,732 will issue on July 15, 2008 as U.S. patent number 7,399,772. The new patent has claims covering methods for treating acid-caused gastrointestinal disorders by administering a solid pharmaceutical composition comprising non-enteric coated omeprazole and certain antacids. A Notice of Allowance was sent by the USPTO in April 2008. The new patent will have a July 2016 expiration date.

Encore Networks Announces the Issuance of a U.S. Patent Relating to its Selective Layer Encryption for Broadband Satellite Networks

Encore Networks, a leading supplier of industrially hardened VPN based network security appliances, today announced that it has been granted a patent by the U.S. Patent and Trademarks Office under U.S. Patent Number 7,360,083. This patent relates to Encore’s innovative method for providing security solutions to aid protocol acceleration over satellite networks using Selective Layer Encryption (SLE). SLE is an encryption technology that securely connects satellite networks with terrestrial links as part of an end-to-end Virtual Private Network (VPN) solution.

Encore Networks Announces the Issuance of a U.S. Patent Relating to its Selective Layer Encryption for Broadband Satellite Networks

Encore Networks, a leading supplier of industrially hardened VPN based network security appliances, today announced that it has been granted a patent by the U.S. Patent and Trademarks Office under U.S. Patent Number 7,360,083. This patent relates to Encore

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Visto Patent Ruled Valid by U.S. Patent and Trademark Office

PRNewswire/ -- Visto(R) Corporation today announced that the U.S. Patent and Trademark Office (USPTO) has validated one of its patents that had been submitted for re-exam. Twenty-one of the claims for U.S. Patent No. 7,039,679 (the '679 patent) were confirmed and ruled patentable.

Visto Patent Ruled Valid by U.S. Patent and Trademark Office

REDWOOD CITY, Calif., July 2 /PRNewswire/ -- Visto® Corporation today announced that the U.S. Patent and Trademark Office (USPTO) has validated one of its patents that had been submitted for re-exam. Twenty-one of the claims for U.S. Patent No. 7,039,679 (the '679 patent) were confirmed and ruled patentable.

Visto Patent Ruled Valid by U.S. Patent and Trademark Office

REDWOOD CITY, Calif., July 2 /PRNewswire/ -- Visto(R) Corporation today announced that the U.S. Patent and Trademark Office (USPTO) has validated one of its patents that had been submitted for re-exam. Twenty-one of the claims for U.S. Patent No. 7,039,679 (the '679 patent) were confirmed and ruled patentable.

Visto Patent Ruled Valid by U.S. Patent and Trademark Office

REDWOOD CITY, Calif., July 2 /PRNewswire/ -- Visto(R) Corporation today announced that the U.S. Patent and Trademark Office (USPTO) has validated one of its patents that had been submitted for re-exam. Twenty-one of the claims for U.S. Patent No. 7,039,679 (the '679 patent) were confirmed and ruled patentable.

Visto Patent Ruled Valid by U.S. Patent and Trademark Office

REDWOOD CITY, Calif., July 2 /PRNewswire/ -- Visto(R) Corporation today announced that the U.S. Patent and Trademark Office (USPTO) has validated one of its patents that had been submitted for re-exam. Twenty-one of the claims for U.S. Patent No. 7,039,679 (the '679 patent) were confirmed and ruled patentable.

Visto Patent Ruled Valid by U.S. Patent and Trademark Office

REDWOOD CITY, Calif., July 2 /PRNewswire/ -- Visto(R) Corporation today announced that the U.S. Patent and Trademark Office (USPTO) has validated one of its patents that had been submitted for re-exam. Twenty-one of the claims for U.S. Patent No. 7,039,679 (the '679 patent) were confirmed and ruled patentable.

Visto Patent Ruled Valid by U.S. Patent and Trademark Office

REDWOOD CITY, Calif., July 2, 2008 /PRNewswire via COMTEX/ -- RIMM | Quote | Chart | News | PowerRating -- Visto(R) Corporation today announced that the U.S. Patent and Trademark Office (USPTO) has validated one of its patents that had been submitted for re-exam. Twenty-one of the claims for U.S. Patent No. 7,039,679 (the '679 patent) were confirmed and ruled patentable.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich., BUSINESS WIRE -- ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich.--(BUSINESS WIRE)--Jul 4, 2008 - ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Advanced Biological Laboratories Patent Licensing Technologies SARL Enters U.S. Patent License Agreement With Viralliance Inc.

LUXEMBOURG & KALAMAZOO, Mich.--(BUSINESS WIRE)--July 4, 2008--ABL Patent Licensing Technologies, SARL, a subsidiary of Advanced Biological Laboratories SA (ABL) entered into a patent licensing agreement with Viralliance Inc. (VI). As per the scope of the patent license agreement, ABL has granted a non-exclusive, royalty-bearing license to VI to use the ABL patent portfolio for guiding and ranking the selection of a therapeutic regimen for a given patient. The other terms of the agreement are confidential.

Supreme Court strengthens patent exhaustion doctrine

The United States Supreme Court has unanimously held in Quanta Computer, Inc. v. LG Electronics, Inc. that the patent law cannot be used to control the subsequent use or disposition of a product "that substantially embodies a patent" once the product has been sold with authority of the patent owner. "The authorized sale of an article that substantially embodies a patent exhausts the patent holder's rights and prevents the patent holder from invoking the patent law to control post-sale use of the article." Patent exhaustion applies whether the patents are directed to products or methods. "Our precedents do not differentiate transactions involving embodiments of patented methods or processes from those involving patented apparatuses or materials.

Search took 0.49 seconds.